Phase 3 N=366 Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Motion Sickness
Primary: Prevention of Vomiting Measured by Vomiting Assessment (VA) — 22; 24; 54 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=29 Non-pharmaceutical Motion Sickness Mitigation
Healthy
Primary: Motion Perception — 55.3; 49.7; 50.1 score on a scale
Phase 2 N=126 Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Motion Sickness
Primary: The Most Severe Motion Sickness Severity During Vehicle Travel — 3.4; 3.75 units on a scale
Phase 3 N=316 Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
Motion Sickness
Primary: Prevention of Vomiting Measured by Vomiting Assessment (VA) — 11; 19; 40 Participants
N/A N=27 Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?
Migraine
Primary: Change From Baseline in Motion Sickness to Post Vestibular Stimulus — 5.1; 9 units on a scale — p=0.007
Phase 4 N=30 Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels
Vestibular
Primary: Percent Change in Roll Tilt Perception After Exposure to Hypogravity — 27.0 percentage change
N/A N=10 Sensory Training for Visual Motion Sickness
Dizziness · Vertigo · Motion Sickness
Primary: Rod and Disk Test (RDT) Mean Performance — 17; 13.3; 7.8; 12.1 degrees
N/A N=47 Treatments of Mal de Debarquement Syndrome (MdDS) by Habituation of Velocity Storage
Mal de Debarquement Syndrome (MdDS)
Primary: Subjective Symptoms Self-report of Overall Severity — 5.2; 5.2; 3.2; 2.1 score on a scale
N/A N=24 Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome
Mal de Debarquement Syndrome
Primary: Dizziness Handicap Inventory — -17.5; -3.7; -8.4; -10.1 score on a scale — p=0.0439
Phase 4 N=289 The Montefiore Metoclopramide Study
Nausea · Extrapyramidal Symptoms
Primary: Nausea Scale — 0; 0; 0; 0 units on a scale
N/A N=78 Vestibular Testing: Consistency and Effects Over Time
Dizziness
Primary: Vestibular Reaction Times — 240.89; 202.96; 233.09; 228.95 msec
N/A N=51 EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron
Nausea
Primary: Time to Nausea Reduction by 50% by Visual Analog Scale. — 4.3; 3.5 Minutes
Phase 3 N=706 Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
Migraine
Primary: Long-term Safety of Chronic Intermittent Use of AXS-07 — 293; 118; 8; 10 Participants
Phase 2 N=40 Galcanezumab for Vestibular Migraine
Vestibular Migraine
Primary: Change in VM-PATHI (Vestibular Migraine-Patient Assessment Tool and Handicap Inventory) Score From Baseline to Month 4 — -14.8; -5.1 score on a scale
N/A N=41 Effects of Lifestyle Modification on Vestibular Migraine
Vestibular Migraine
Primary: Headache Disability Inventory (HDI) — 14.3 score on a scale — p=<.0001
N/A N=6 Vestibular Rehabilitation and Otolith Dysfunction
Dizziness
Primary: Change in Static Subjective Visual Vertical (SVV) — 0.69; 0.58; 0.69; 0.89 degrees — p=0.97
Phase 3 N=134 Rizatriptan for Episodic Dizziness in Vestibular Migraine
Vestibular Migraine · Migrainous Vertigo
Primary: Episodes With Vertigo Symptom Reduced From Moderate/Severe to None/Mild — 50; 73 Episodes — p=<0.33
Phase 2 N=107 Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy
Acute Unilateral Vestibulopathy (AUV)
Primary: Standing Vertigo Intensity — 165.10; 155.10; 136.60 mm*day — p=0.8466
N/A N=23 Recovery of Visual Acuity in People With Vestibular Deficits
Vestibular Neuronitis · Vestibular Neuronitis, Bilateral · Vestibular Schwannoma
Primary: Change in Visual Acuity During Head Movement From Baseline to Discharge — 0.198; .296 LogMAR
Phase 2 N=75 Meclizine as a Potential Smoking Cessation Treatment
Smoking Cessation
Primary: Percentage of Change in Expired Air Carbon Monoxide (CO) at End of Week 1 — 1.73; -14.11; -.63 percentage change
N/A N=242 Alternative Approaches for Nausea Control
Nausea
Primary: Patient Report Nausea Diary — 3.87; 3.55; 3.52 units on a scale — p=.05
N/A N=30 Virtual Environments for Vestibular Rehabilitation
Dizziness Chronic · Vertigo, Peripheral · Fall
Primary: Visual Vertigo Analog Scale (VVAS) — 43.05; 36.84; 31.28; 21.41 score on a scale — p=0.027
N/A N=17 "Can A Prescribed Walking Program With or Without Monitoring Impact Dizziness in the Older Adults?"
Dizziness
Primary: Modified Clinical Test of Sensory Integration for Balance (mCTSIB) — 115.98; 97.4; 110.15; 107.23 seconds — p=.640
Phase 3 N=18 Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion
Healthy · Hypoxia
Primary: SpO2 Accuracy During Motion Conditions - MaxA Sensor — 1.78 Accuracy Root Mean Square
N/A N=46 Vestibular Stimulation in Parkinson's Disease
Parkinson's Disease
Primary: Change From Baseline in the Nonmotor Symptom Severity Scale (NMSS) — -33.5; -2.0 change in scale total score — p=0.0089
N/A N=10 Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus
Nystagmus
Primary: Change in logMAR Visual Acuity of Each Eye, Measured During Far or Near Viewing — 0; 0.1; 0.2; 0.2 logMAR
Phase 2 N=130 Acute Video-oculography for Vertigo in Emergency Rooms for Rapid Triage (AVERT)
Vertigo · Dizziness
Primary: VRT vs. ED SOC Six-Category Diagnosis Accuracy (Primary Analysis-eligible Participants, Two-arm Comparison) — 24; 18; 33; 38 Participants
N/A N=24 Computerized Vestibular Rehabilitation
Vestibular Diseases
Primary: Vestibulo-ocular Reflex Gain Ratio — 1.15 unitless gain ratio — p=<0.001
N/A N=23 Vestibular Intervention Via Portable Electrical Stimulator (VIPES)
Balance Disorder
Primary: Change in Balance Performance — 0.52; 0.42; 0.51; 0.48 degrees per second
Phase 4 N=9 Lundbeck TOMs Orthostatic Hypotension
Orthostatic Hypotension · Idiopathic Parkinson Disease
Primary: Orthostatic Hypotension Questionnaire (OHQ) Score — 4.6 score on a scale